Doravirine/lamivudine/tenofovir disoproxil fumarate - Merck

Drug Profile

Doravirine/lamivudine/tenofovir disoproxil fumarate - Merck

Alternative Names: MK-1439/lamivudine/tenofovir disoproxil fumarate; MK-1439A

Latest Information Update: 29 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Nitriles; Phosphonic acids; Purines; Pyridones; Pyrimidine nucleosides; Small molecules; Triazoles
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration HIV-1 infections

Most Recent Events

  • 01 May 2018 Preregistration for HIV-1 infections (Adjunctive treatment) in European Union (PO) (Merck pipeline, May 2018)
  • 08 Jan 2018 FDA assigns PDUFA action date of 23/10/2018 for doravirine for HIV-1 infections (Treatment-naive)
  • 08 Jan 2018 Preregistration for HIV-1 infections (Treatment-naive) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top